Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (11-20 of 346) with videos related to

Pageof 35
Sort By:
The Lancet. Haematology|June 30, 2022
Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemiaNicholas J Short, Hagop Kantarjian
Expert Review of Hematology|May 10, 2016
The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical reviewNicholas J Short, Farhad Ravandi
American Journal of Hematology|July 24, 2022
Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directionsNicholas J Short, Hagop Kantarjian
Clinical Lymphoma, Myeloma & Leukemia|September 1, 2020
Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of CareNicholas J Short, Elias Jabbour
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern EraNicholas J Short, Hagop Kantarjian
Biologics : Targets & Therapy|February 28, 2020
Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted ImmunotherapyMiguel J Franquiz, Nicholas J Short
Blood Advances|May 14, 2025
Response to "It might not be whether you get knocked down, but whether you..."Wei Ying Jen, Nicholas J Short
American Journal of Hematology|September 27, 2023
Treatment discontinuation in chronic myeloid leukemia: When, how, and why?Fadi G Haddad, Nicholas J Short
The Oncologist|December 10, 2013
New oral anticoagulants and the cancer patientNicholas J Short, Jean M Connors
Hematology. American Society of Hematology. Education Program|December 9, 2022
Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?Fadi G Haddad, Nicholas J Short
Pageof 35

Showing results (11-20 of 346) with videos related to

Sort By:
Pageof 35
The Lancet. Haematology|June 30, 2022
Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemiaNicholas J Short, Hagop Kantarjian
Expert Review of Hematology|May 10, 2016
The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical reviewNicholas J Short, Farhad Ravandi
American Journal of Hematology|July 24, 2022
Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directionsNicholas J Short, Hagop Kantarjian
Clinical Lymphoma, Myeloma & Leukemia|September 1, 2020
Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of CareNicholas J Short, Elias Jabbour
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2021
When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern EraNicholas J Short, Hagop Kantarjian
Biologics : Targets & Therapy|February 28, 2020
Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted ImmunotherapyMiguel J Franquiz, Nicholas J Short
Blood Advances|May 14, 2025
Response to "It might not be whether you get knocked down, but whether you..."Wei Ying Jen, Nicholas J Short
American Journal of Hematology|September 27, 2023
Treatment discontinuation in chronic myeloid leukemia: When, how, and why?Fadi G Haddad, Nicholas J Short
The Oncologist|December 10, 2013
New oral anticoagulants and the cancer patientNicholas J Short, Jean M Connors
Hematology. American Society of Hematology. Education Program|December 9, 2022
Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?Fadi G Haddad, Nicholas J Short
Pageof 35